HK Stock Movement | PEGBIO CO-B (02565) Surges Over 20% at Close to Hit New High, Secures Exclusive License for Diabetes Drug in Middle East & Africa

Stock News

Oct 31

PEGBIO CO-B (02565) surged over 20% in late trading, reaching a record high of HK$62.25. At the time of writing, the stock was up 16.51% at HK$60.3, with a turnover of HK$30.23 million.

The company recently announced a strategic partnership with UAE-based pharmaceutical R&D leader PDC FZ-LLC, granting it exclusive rights to develop, distribute, market, and commercialize PEGBIO's flagship product, Visepegenatide (PB-119), in the Middle East and Africa. This collaboration marks a critical milestone in PEGBIO's global commercialization strategy.

Visepegenatide (PB-119) is PEGBIO's self-developed once-weekly subcutaneous GLP-1 receptor agonist for treating type 2 diabetes and weight management. According to the International Diabetes Federation, the adult diabetes prevalence rate in the Middle East and North Africa stands at 16.2%, the highest globally. This partnership is expected to accelerate access to Visepegenatide (PB-119) for patients with unmet medical needs in the region.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1121128950"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1121128950\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1121128950?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 15:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1121128950","market":"other","top_or_hot":-1,"title":"HK Stock Movement | PEGBIO CO-B (02565) Surges Over 20% at Close to Hit New High, Secures Exclusive License for Diabetes Drug in Middle East & Africa","media":"Stock News","content":"<p>PEGBIO CO-B (02565) surged over 20% in late trading, reaching a record high of HK$62.25. At the time of writing, the stock was up 16.51% at HK$60.3, with a turnover of HK$30.23 million.</p>\n<p>The company recently announced a strategic partnership with UAE-based pharmaceutical R&D leader PDC FZ-LLC, granting it exclusive rights to develop, distribute, market, and commercialize PEGBIO's flagship product, Visepegenatide (PB-119), in the Middle East and Africa. This collaboration marks a critical milestone in PEGBIO's global commercialization strategy.</p>\n<p>Visepegenatide (PB-119) is PEGBIO's self-developed once-weekly subcutaneous GLP-1 receptor agonist for treating type 2 diabetes and weight management. According to the International Diabetes Federation, the adult diabetes prevalence rate in the Middle East and North Africa stands at 16.2%, the highest globally. This partnership is expected to accelerate access to Visepegenatide (PB-119) for patients with unmet medical needs in the region.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HK Stock Movement | PEGBIO CO-B (02565) Surges Over 20% at Close to Hit New High, Secures Exclusive License for Diabetes Drug in Middle East & Africa</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHK Stock Movement | PEGBIO CO-B (02565) Surges Over 20% at Close to Hit New High, Secures Exclusive License for Diabetes Drug in Middle East & Africa\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-10-31 15:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>PEGBIO CO-B (02565) surged over 20% in late trading, reaching a record high of HK$62.25. At the time of writing, the stock was up 16.51% at HK$60.3, with a turnover of HK$30.23 million.</p>\n<p>The company recently announced a strategic partnership with UAE-based pharmaceutical R&D leader PDC FZ-LLC, granting it exclusive rights to develop, distribute, market, and commercialize PEGBIO's flagship product, Visepegenatide (PB-119), in the Middle East and Africa. This collaboration marks a critical milestone in PEGBIO's global commercialization strategy.</p>\n<p>Visepegenatide (PB-119) is PEGBIO's self-developed once-weekly subcutaneous GLP-1 receptor agonist for treating type 2 diabetes and weight management. According to the International Diabetes Federation, the adult diabetes prevalence rate in the Middle East and North Africa stands at 16.2%, the highest globally. This partnership is expected to accelerate access to Visepegenatide (PB-119) for patients with unmet medical needs in the region.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"399441","symbol_name":"生物医药","start_time":0,"source_url":"","article_id":"1121128950","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1121128950","pubTimestamp":1761896419,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"PEGBIO CO-B (02565) surged over 20% in late trading, reaching a record high of HK$62.25. At the time of writing, the stock was up 16.51% at HK$60.3, with a turnover of HK$30.23 million. The company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"161726":"生物医药","399441":"生物医药","02565":"派格生物医药-B","BK1161":"生物科技"},"translate_title":"港股动向|派格生物CO-B(02565)收盘大涨逾20%创新高获中东及非洲糖尿病药物独家授权","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"161726":1,"399441":1,"02565":1},"content_text":"PEGBIO CO-B (02565) surged over 20% in late trading, reaching a record high of HK$62.25. At the time of writing, the stock was up 16.51% at HK$60.3, with a turnover of HK$30.23 million.\nThe company recently announced a strategic partnership with UAE-based pharmaceutical R&D leader PDC FZ-LLC, granting it exclusive rights to develop, distribute, market, and commercialize PEGBIO's flagship product, Visepegenatide (PB-119), in the Middle East and Africa. This collaboration marks a critical milestone in PEGBIO's global commercialization strategy.\nVisepegenatide (PB-119) is PEGBIO's self-developed once-weekly subcutaneous GLP-1 receptor agonist for treating type 2 diabetes and weight management. According to the International Diabetes Federation, the adult diabetes prevalence rate in the Middle East and North Africa stands at 16.2%, the highest globally. This partnership is expected to accelerate access to Visepegenatide (PB-119) for patients with unmet medical needs in the region.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}